DC Combined With ICIs in the Treatment of Advanced Lung Cancer Resistant to ICIs

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 27, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

October 31, 2026

Conditions

Lung Cancer

Interventions

DRUG

LG002

Neo-DCVac combined with ICIs in the treatment of advanced lung cancer resistant to ICIs.

Trial Locations (1)

RECRUITING

West China Hospital, Chengdu

All Listed Sponsors

lead

Zhen-Yu Ding

OTHER